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Abstract
The loss of dopaminergic neurons and α-synuclein accumulation are major hallmarks of Parkinson’s disease (PD), and it has
been suggested that a major mechanism of α-synuclein toxicity is microglial activation. The lack of animal models that properly
reproduce PD, and particularly the underlying synucleinopathy, has hampered the clarification of PD mechanisms and the
development of effective therapies. Here, we used neurospecific adeno-associated viral vectors serotype 9 coding for either
the wild-type or mutated forms of human alpha-synuclein (WT and SynA53T, respectively) under the control of a synapsin
promoter to further induce a marked dopaminergic neuron loss together with an important microglial neuroinflammatory
response. Overexpression of neuronal alpha-synuclein led to increased expression of angiotensin type 1 receptors and
NADPH oxidase activity, together with a marked increase in the number of OX-6-positive microglial cells and expression of
markers of phagocytic activity (CD68) and classical pro-inflammatory/M1 microglial phenotype markers such as inducible nitric
oxide synthase, tumor necrosis factor alpha, interleukin-1β, and IL-6. Moreover, a significant decrease in the expression of
markers of immunoregulatory/M2 microglial phenotype such as the enzyme arginase-1 was constantly observed. Interestingly,
alpha-synuclein-induced changes in microglial phenotype markers and dopaminergic neuron death were inhibited by simulta-
neous treatment with the angiotensin type 1 blockers candesartan or telmisartan. Our results suggest the repurposing of
candesartan and telmisartan as a neuroprotective strategy for PD.
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Introduction
Parkinson’s disease (PD) is the second most common neuro-
degenerative disorder. The loss of dopaminergic neurons and
alpha-synuclein (α-syn) accumulation are major hallmarks of
the disease. The etiology of PD appears multifactorial and
remains largely unknown. However, regardless of the cause,
it is known that oxidative stress (OS) and neuroinflammation
are the major factors for progression of the disease [1–3].
Alpha-syn is a 140-amino-acid protein, predominantly located
in the presynaptic terminals, and a major component of Lewy
bodies. It has been associated to the regulation of neurotrans-
mitter release, regulation of synaptic vesicles, and microtubule
dynamics [4, 5]. The pathogenic role of insolubleα-syn is less
known. However, microglial activation has been suggested as
a major mechanism of α-syn toxicity [6].
One factor that has hampered the development of effective
therapies is the lack of animal models that properly reproduce
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the synucleinopathy that characterizes PD reviewed in Koprich
et al. [7], Sarkar et al. [8], and Visanji et al. [9]. Several models
of transgenic mice overexpressing wild-type (WT) or mutated
forms of human α-syn have been used to better understand the
effects of α-syn accumulation [10]. However, these models
were not adequate to induce a progressive and marked neuro-
degeneration and other major pathologic changes observed in
PD. More recent models induced overexpression of α-syn
using viral vectors, particularly adeno-associated viral (AAV)
vectors [11, 12]. Several AAV serotypes have been used so far
(AAV2, 5, and 6), althoughmost of them have shown problems
to induce adequate expression levels and significant pathology.
However, more efficient AAV vector constructs led to efficient
dopaminergic neuronal loss and behavioral deficits [13, 14]. An
intense neuroinflammatory response was observed after induc-
tion of α-syn overexpression using AAV vectors [15, 16],
which suggests that therapies that inhibit the α-synuclein-
induced neuroinflammatory response may be an effective neu-
roprotective strategy against the progression of dopaminergic
neuron degeneration.
The brain renin angiotensin system (RAS) mediates
microglial polarization as angiotensin (Ang II), via its type 1
(AT1) receptor, is a major activator of the microglial NADPH
oxidase complex, which enhances the neuroinflammatory re-
sponse [17, 18]. Consistent with this, our previous studies
showed that AT1 activation exacerbates the microglial inflam-
matory response, oxidative stress, and dopaminergic degenera-
tion in 6-hydroxydopamine and MPTP models of PD, which
was inhibited by AT1 receptors blockers [19–21]. In this study,
we used a AAV serotype 9 (AAV9) with a small fragment of the
human synapsin 1 gene promoter to restrict transgene expres-
sion exclusively to neurons [22], and we obtained stable long-
term transgene expression of WT or mutated (A53T) forms of
humanα-syn that induced neuron degeneration in the substantia
nigra pars compacta (SNpc). In this model, we investigated the
α-syn-induced microglial response and its possible inhibition
with AT1 receptor blockers (candesartan, telmisartan), which
is particularly interesting since these drugs are currently used
in clinical practice for cardiovascular diseases.
Materials and Methods
Experimental Design
Adult male Sprague-Dawley rats (8-10 weeks old at the be-
ginning of the experiments; n = 220) were used in the present
study. The animals were housed in environmentally controlled
conditions: 12:12-h light/dark conditions at constant room
temperature (21 ± 1 °C) with access to food and water ad
libitum. All experiments were carried out in accordance with
the European Communities Council Directive 2010/63/EU
and Directive 86/609/EEC and were approved by the
corresponding committee at the University of Santiago de
Compostela. All surgery was performed under ketamine/
medetomidine anesthesia. The rats were divided into 3 major
groups. Rats in group Awere injected in the right mesenceph-
alon (close to the substantia nigra) with 2 μl of neurospecific
AAV9 expressing human WT α-syn and were randomly di-
vided into 3 subgroups: rats in subgroup A1 (n = 32) were
simultaneously treated with vehicle, rats in subgroup A2
(n = 28) were simultaneously treated with the AT1 receptor
antagonist candesartan, and rats in subgroup A3 (n = 28) were
simultaneously treated with the AT1 receptor antagonist
telmisartan (see below). Rats in group B were injected in the
right mesencephalon (close to the substantia nigra) with 1 μl
of AAV9 expressing human A53T mutated α-syn, using the
procedure described above for group A. Once injected, ani-
mals were randomly divided into 3 subgroups: rats in sub-
group B1 (n = 28) were simultaneously treated with vehicle,
rats in subgroup B2 (n = 24) were treated with the AT1 recep-
tor antagonist candesartan, and rats in subgroup B3 (n = 24)
were treated with the AT1 receptor antagonist telmisartan.
Rats in group C were used as controls and injected in the right
mesencephalon with 2 μl of saline (group C1; n = 17), or
neurospecific empty-null (Ф) AAV9 vectors (AAV9-null;
group C2; n = 29), or neurospecific AAV9 expressing human
green fluorescent protein (GFP) (group C3; n = 10). Rats from
the different groupswere sacrificed 1week (n = 50) or 4 weeks
(n = 170) after the nigral injection.
After the survival period, parts of the rats in the different
groups (n = 50) were perfused and prepared for histological
studies to investigate overexpression of α-syn or GFP or phos-
phorylated α-syn in dopaminergic neurons (TH-ir, tyrosine hy-
droxylase-immunoreactive), microglial cells (Iba-1-ir, ionized
calcium-binding adapter molecule 1), and astrocytes (GFAP-
ir, glial fibrillary acidic protein) in SNpc using double immu-
nofluorescence and laser-scanning confocal microscopy, or his-
tochemistry for dopaminergic cell death (TH-ir, counterstained
with Nissl staining) or the microglial response (OX6-ir). In a
second series of rats from different groups, brains were rapidly
removed, immediately frozen in liquid nitrogen, and stored at −
80 °C until processed for determination of levels of RAS activ-
ity (AT1 receptor expression, NADPH oxidase activity),
markers of phagocytic activity (CD68, cluster of differentiation
68), and markers of M1 (iNOS, inducible nitric oxide synthase;
TNF-α, tumor necrosis factor alpha, interleukin (IL)-1β, IL-
1β, and IL-6) and M2 (ARG-1, arginase-1) microglial pheno-
types, using real-time quantitative RT-PCR, chemilumines-
cence, and enzyme immunoassay studies (see below).
Synthesis and Purification of Adeno-Associated
Vectors
Recombinant single-stranded AAV9 vectors were produced in
our in-house facilities by a cotransfection using linear
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polyethylenimine 25 kDa (Polysciences, Warrington, PA)
with 2 different plasmids: a plasmid containing the adenovirus
helper genes, plus AAV2 rep and AAV9 cap, and a plasmid
containing the transgenes of interest (either SynA53T,
SynWT, eGFP, or without transgene) under the control of
the human synapsin promoter, flanked by the AAV2 internal
terminal repeat sequences. Viral vector particles were harvest-
ed from human embryonic kidney 293T cells (HEK293T)
after 72 h posttransfection, resuspended in a lysis buffer
(50 nM Tris–HCl, 150 nM NaCl, 2 mM MgCl2, 0.1% Triton
X-100) and stored at − 80 °C until used. Viral particles were
purified by ultracentrifugation in an iodoxanol gradient and
were concentrated through centricon tubes (YM-100;
Millipore, Bedford, MA). Viral titers were determined by
quantitative PCR for viral genomic copies extracted from
DBAse-treated viral particles using WPRE-directed primers
(FW: CGCAACCCCACTGGTT and RV: AAAGCGAA
AGTCCCGCAAAG). Obtained vector titers ranged from
1.8 × 1012 to 2 × 1012 vg/ml (viral genomes/ml).
Stereotaxic Injections and Candesartan
and Telmisartan Administration
Injections were performed in the right mesencephalon dorsal
to the nigra to minimize possible traumatic damage.
Stereotaxic coordinates were − 5.4 mm anterior to bregma,
− 1.9 mm right of midline, and − 7.0 mm ventral to the dura;
tooth bar was at − 2.3 mm [23]. The viral vectors were injected
using a 5-μl Hamilton syringe coupled to a motorized injector
(Stoelting, Wood Dale, IL). Injections were accomplished in
pulses of 0.5 μl/min (2 μl for the AAV9-WT α-syn-injected
group and 1 μl for the AAV9-A53T α-syn-injected group),
and once completed, the microsyringe was left in place for an
additional time of 10 min before withdrawal, to avoid viral
vector reflux through the injection tract. Groups of animals
received oral treatment with the AT1 receptor antagonists
candesartan (groups A2 and B2 1 mg/kg/day; AstraZeneca,
Madrid, Spain) or telmisartan (groups B2 and B3; 1 mg/kg/
day; Sigma, St. Louis, MO) from 2 weeks before AAV9 in-
jection until they were sacrificed. The doses were selected on
the basis of the results of our previous studies [24, 25]. The
powered drug was administered orally mixed with BNocilla^
hazelnut cream (Nutrexpa, Barcelona, Spain). Animals in con-
trol groups were given BNocilla^ hazelnut cream only.
Double/Triple Immunofluorescence and Laser
Confocal Microscopy
One or 4 weeks after the stereotaxic injections, rats were first
transcardially perfused with 0.9% saline and then with cold
4% paraformaldehyde in 0.1 M phosphate-buffered saline, pH
7.4. The brains were removed, washed and cryoprotected in
the same buffer containing 20% sucrose, and finally cut into
40-μm sections on a freezing microtome and stored in a cryo-
protectant solution at − 20 °C until processing.
Double immunofluorescence labeling was performed to iden-
tify cells expressing GFP,α-syn, and phosphorylatedα-syn. The
antibodies against α-syn were combined with TH or GFAP or
Iba-1 to study the possible colocalization with these cell type
markers. Free-floating tissue sections were heated at 37 °C for
30 min in sodium citrate buffer (10 mM sodium citrate, 0.05%
Tween 20, pH 6.0). After antigen retrieval, tissue sections were
pre-incubated in potassium phosphate-buffered saline (KPBS)–
1% bovine serum albumin (BSA) with 5% normal donkey se-
rum (Sigma) for 60 min at room temperature and then incubated
overnight at 4 °C in the correspondingmix of primary antibodies
raised againstα-synuclein (mouse IgG, 1:500, ab80627, Abcam,
Cambridge, England, UK, forWTsynuclein; mouse IgG, 1:200,
18-0215, Invitrogen, Paisley, UK, for A53T synuclein), phos-
phorylated α-syn (rabbit IgG, 1:1000, ab51253, Abcam), TH
(rabbit IgG, 1:1000 ab152, Millipore; or mouse IgG, 1:10,000,
T2928, Sigma), GFAP (mouse IgG, 1:500; MAB360,
Millipore), and Iba-1 (rabbit IgG, 1:500, 019-19741, Wako,
Richmond, VA) diluted in KPBS–1% BSA with 4% normal
donkey serum. Finally, the immunoreaction was visualized with
the corresponding fluorescent secondary antibodies: Alexa Fluor
568-conjugated donkey anti-rabbit IgG (1:200, Molecular
Probes, Eugene, OR) and Alexa Fluor 488-conjugated donkey
anti-mouse IgG (1:200, Molecular Probes). Finally, tissue sec-
tions were incubated for 30 min at RT with the DNA-binding
dye Hoechst 33342 (3 × 10−5 M, Sigma), in KPBS, mounted on
gelatin-coated slides and coverslipped with Shandon Immu-
Mount (Thermo fisher Scientific, Waltham, MA). Tissue sec-
tions were visualized using a confocal laser scanningmicroscope
(AOBS-SP5X; Leica Microsystems Heidelberg GmbH,
Mannheim, Germany). For colocalization analysis, 3 images of
the substantia nigra per animal were obtained at different coor-
dinates of its anteroposterior axis (− 5.20, − 5.60, and − 6.04mm
from bregma). Images were obtained by laser scanning micros-
copy with the aid of a × 10 objective and using constant micro-
scope parameters and similar laser intensity. The substantia nigra
was delimited in each image and the rate of colocalization of TH
and P(Ser129)-syn was measured by using the LAS AF Lite
software (Leica).
Western Blot
For Western blot analysis of α-syn and phosphorylated α-syn,
the nigral region in the ventral mesencephalon was dissected and
the tissue was homogenized in radioimmunoprecipitation assay
buffer containing protease inhibitor cocktail (P8340, Sigma),
phenylmethylsulfonyl fluoride (P7626, Sigma), and phosphatase
inhibitor cocktail (P5726, Sigma). For determination of α-synu-
clein, the resulting homogenates were centrifuged for 20 min at
12,000×g. For phosphorylated α-synuclein, samples were proc-
essed as previously described [14] with slight modifications.
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Briefly, homogenates were incubated for at least 1 h in ice, then
samples were centrifuged for 30 min at 120,000×g and the
resulting supernatants were recollected. Both for α-synuclein
and phosphorylated α-synuclein, protein concentrations were
determined by the Bradford protein assay. Equal amounts of
protein (35 μg) were separated by 5 to 10% Bis–Tris polyacryl-
amide gel and transferred to nitrocellulose membrane. Then, the
membranes were treated with 0.4% PFA for 30 min at room
temperature before blocking them with phosphoblocker (10%,
AKR-103, Cell Biolabs, San Diego, CA). The membranes were
incubated overnight with primary antibodies againstα-synuclein
(1:1000, ab138501, Abcam) or phosphorylated α-synuclein
(1:1000, ab51253, Abcam). The HRP-conjugated secondary an-
tibody used was mouse anti-rabbit (1:2500, sc-2357, Santa Cruz
Biotechnology, Dallas, TX). Immunoreactivity was detected
with an Immun-Star HRP Chemiluminescent Kit (170-5044,
Bio-Rad; Hercules, CA) and visualized with a chemilumines-
cence detection system (Molecular Imager ChemiDoc XRS
System, Bio-Rad). Blots were stripped and reprobed for anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(1:25,000, G9545, Sigma) as loading control.
Immunohistochemistry, Nissl Staining,
and Stereological Analysis
TH and OX6 staining were used to label dopaminergic cells
and classically activated microglia, respectively. The mouse
monoclonal MHC class II antibody (OX6) was selected be-
cause microglial MHCII expression has been shown to be
strikingly induced by α-syn in vitro and in vivo, and it is
known that the expression of MHCII plays a major role in
both the innate and the adaptive immune response [26].
Sections were incubated for 1 h in 10% normal serum with
0.25% Triton X-100 in 20 mM KPBS containing 1% BSA
(KPBS–BSA), then incubated overnight at 4 °C with mouse
monoclonal antiserum to TH (1:10,000, T2928, Sigma) or
mouse monoclonal MHC class II antibody (OX6,
1:50, MCA46G, Bio-Rad) at 4 °C in 20mMKPBS containing
1% BSA, 2% normal serum, and 0.25% Triton X-100. The
following day, the sections were incubated, firstly for 90 min
with the corresponding biotinylated secondary antibodies
(1:200), and then for 90min with an avidin–biotin–peroxidase
complex (1:50, Vector, Burlingame, CA). Finally, the labeling
was visualized with 0.04% hydrogen peroxide and 0.05%
3,3′-diaminobenzidine (Sigma), containing 0.1% nickel sul-
fate to intensify the microglial staining. For negative control
staining, sections were incubated in media lacking primary
antibodies. In order to confirm dopaminergic cell death and
not just phenotypic downregulation in TH activity, series of
sections through the entire substantia nigra of control and
treated rats were counterstained with Cresyl violet. Brain sec-
tions were mounted on gelatin-coated glass slides and stained
for 5 min with 1% Cresyl violet (C0775, Sigma) dissolved in
distilled water. Then, stained sections were dehydrated
through graded ethanol (100%, 95%, 70%, and 50%), cleared
in xylene for 5 min, covered with DPX mounting medium
(Panreac Applichem, Barcelona, Spain), and coverslipped.
Finally, the total number of neurons in the SNc was estimated
using the unbiased stereology method (see below).
The total number of TH-ir neurons and OX6-ir density in
the substantia nigra was estimated by an unbiased stereologi-
cal method (the optical fractionator) using anOlympus CAST-
Grid system (Computer Assisted Stereological Toolbox;
Olympus, Ballerup, Denmark). Uniform randomly chosen
sections through the SNpc (every fourth section) from the
different groups were analyzed for the total number of TH-ir
or OX6-ir cells by means of a stereological grid (fractionator),
and the nigral volume was estimated according to Cavalieri’s
method [27]. To confirm that overexpression of α-syn pro-
moted dopaminergic neuron death, series of sections through
the entire SNpc of control and treated rats were counterstained
with Cresyl violet, and the total number of neurons in the
SNpc was estimated by the unbiased stereology method de-
scribed above for TH-ir cells. Neurons were distinguished
from glial cells on a morphological basis, and neurons with
visible nuclei were counted as above for TH-ir neurons. For
details, see Rey et al. [20].
The density of striatal dopaminergic terminals was estimat-
ed as the optical density of the striatal TH-ir with the aid of
NIH-Image 1.55 image analysis software (National Institutes
of Health, Bethesda, MD) in a personal computer coupled to a
videocamera (CCD-72, DAGE-MTI, INC, Michigan City,
IND) and a constant illumination light table (Northern Light,
St. Catharines, Canada). At least 4 sections through the central
striatum of each animal were measured, and for each section,
the optical densities were corrected by subtraction of back-
ground, as observed in the corpus callosum.
High Performance Liquid Chromatography
Dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic
acid (DOPAC) and homovanilic acid (HVA) were measured in
the striata by high-performance liquid chromatography
(HPLC) analysis, as previously described [28]. Briefly, rat
striatal tissue was homogenized and centrifuged (14,000×g
for 20 min at 4 °C). Then, the supernatant fractions were fil-
tered and injected directly into the HPLC (Shimadzu LC prom-
inence, Shimadzu Corporation, Kyoto, Japan). DA, DOPAC,
and HVAwere separated on a reverse phase analytical column
(Waters Symmetry300C18; Waters, Milford, MA). The mobile
phase (pH 4) consisted of 10%MeOH, 70mMKH2PO4, 1mM
octanesulfonic acid, and 1 mM EDTA and was delivered at a
rate of 1 ml/min. Detection was performed with a coulometric
e lec t rochemica l de tec to r (ESA Coulochem II I ;
ESA, Chelmsford, MA). Data were acquired and processed
with the Shimadzu LC solution software (Shimadzu
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Corporation) and were expressed as nanogram per milligram of
wet tissue. The DOPAC/DA ratio was calculated for each ani-
mal as an index of the DA turnover.
Motor Behavioral Analysis: Cylinder Test, Rotarod
Test, and Locomotor Activity
Spontaneous forelimb use was assessed in the cylinder test
[29]. The rats were placed in a glass cylinder (20 cm in diam-
eter), and forelimb use was analyzed by videotaping the ani-
mals as they moved freely in the cylinder and explored the
environment. Mirrors were placed behind the cylinder to al-
low observation of the animals when they were turned away
from the camera. An observer blinded to the identity of the
animals scored the number of forelimb contacts with the cyl-
inder wall. In rats with unilateral dopaminergic denervations,
forelimb asymmetry is expressed as the use of the impaired
paw and expressed as the percentage of the total number of
touches (20 touches were counted for each animal). An unbi-
ased control animal would thus receive a score of 50%,where-
as lesions usually reduce performance of the impaired paw in
this test.
Our original rotarod test [30, 31] was performed with
slight modifications [32], using an automated 4-lane
rotarod uni t (CR-1 Rotamex System, Columbus
Instruments, Columbus, OH). A session protocol with an
accelerated rotational speed was used. Animals were
pretrained during 2 consecutive days to reach a stable per-
formance in the test. For rotarod testing, the rats were
placed on the rod at an initial speed of 4 rpm. Then, the
rod speed was increased to 44 rpm over 90 s, and the total
running time on the rod was recorded. In all cases, tests
were performed on 3 consecutive days, and the results were
averaged to obtain a single value for each rat. Finally, inte-
grated measures for the rotarod performance of each rat
were obtained as the area under the curve (AUC).
Spontaneous locomotor activity was automatically mon-
itored with the aid of a Videomex-X motion analyzer
(Columbus Instruments), which is a video-based apparatus
that monitors the video image in real time (20 frames per
second) [33]. The multiple motion monitor software option
was used to estimate total activity (rate of motion) of each
group of animals. The rate of motion consists of the amount
that the picture changes from 1 frame to the next. The pro-
gram counts the number of pixel changes caused by the
movements of all the animals in the picture. Each group
of animals was acclimatized to the Videomex for at least
10 min, and locomotor activity was monitored for 30 min.
All trials were carried out in a black-walled open-topped
box of 70 × 75 × 40 cm. Data obtained from 3 consecutive
days were used for the analysis and expressed as percentage
of the control group.
RNA Extraction and Real-Time Quantitative Reverse
Transcriptase–Polymerase Chain Reaction
Total RNA from the nigral region was extracted with TRIzol
(Invitrogen), according to the manufacturer’s instructions;
2.5 μg of RNA was reverse-transcribed to complementary
DNA with deoxynucleotide triphosphates, random primers,
and Moloney murine leukemia virus reverse transcriptase
(200 U; Invitrogen). Real-time polymerase chain reaction
was used to examine relative levels of iNOS and ARG-1 mes-
senger RNA. Experiments were performed with a real-time
iCycler polymerase chain reaction platform (Bio-Rad).
GAPDH was used as a housekeeping gene and was amplified
in parallel with the genes of interest. The comparative cycle
threshold values (Ct, cycle threshold) method (2−ΔΔCt) was
used to examine the relative mRNA expression. A normalized
value is obtained by subtracting Ct of GAPDH from Ct of the
interest (ΔCt). As it is uncommon to use ΔCt as relative
expression data due to this logarithmic characteristic, the
2−ΔΔCt parameter was used to express the relative expression
data [34, 35]. Finally, the results were expressed as mean
values ± SEM. Primer sequences were as follows: for iNOS,
forward 5′-AAGCTGCATGTG ACTCCAT-3′, reverse 5′-
GGTGAAGGGTGTCGTGAA-3′; for ARG-1, forward 5′-
ATATCTGCCAAGGACATCGT-3′, reverse 5′-TCCA
CTTCAGTCATTGAGAAATAC-3′; for AT1, forward 5′-
TTCAACCTCTACGCCAGTGTG-3′, reverse 5′-GCCA
AGCCAGCCATCAGC-3′; for CD68, forward 5′-AGAC
GACAATCAACCTACC - 3 ′ , r e v e r s e 5 ′ - ATGC
TGAAGAAATGAGGA-3′; for IL-1β, forward 5′-ATCT
CACACAGCAGCATCTC-3 ′ , r ev e r s e 5 ′ -TAGC
AGGTCGTCATCATC-3′; for IL-6, forward 5′-CAGC
CAGTTGCCTTCTTG-3′, reverse 5′-CCTCTGTGAAGTCT
CCTCTC-3 ′ ; and for β -ac t in , forward 5 ′ -TCGT
GCGTGACATTAAAGAG-3 ′ , r ev e r s e 5 ′ -TGCC
ACAGGATTCCATACC-3′.
TNF-α Quantification
Tissue from rat ventral midbrain was homogenized in
RIPA buffer containing protease inhibitor cocktail
(P8340, Sigma) and phenylmethylsulfonyl fluoride
(P7626, Sigma). The homogenates were centrifuged at
12,000×g for 20 min at 4 °C, and the protein concentra-
tions were determined by the Bradford protein assay. The
levels of TNF-α were quantified with rat specific enzyme-
linked immunosorbent assay kits according to the manu-
facturers’ instructions (rat TNF-α from Diaclone
865.000.96, Gen-Probe Diaclone SAS, Besançon, France).
Finally, TNF-α content was obtained in picograms per
milliliter protein and expressed as percentages of the con-
tent in the control group samples.
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NADPH Oxidase Activity
NADPH oxidase activity in ventral mesencephalic tissue was
measured by lucigenin-enhanced chemiluminescence with an
Infinite M200 multiwell plate reader (TECAN, Salzburg,
Austria), as previously described [36, 37]. Chemiluminescence
was expressed as relative light units (RLU/min/mg protein).
Statistical Analysis
Statistical analyses were carried out with SigmaStat 3.0 from
Jandel Scientific (San Rafael, CA). All values are expressed as
mean ± SEM (n = 4-6). Differences among means were ana-
lyzed using one-way ANOVA followed by a post hoc Holm–
Sidak test. The normality of populations and homogeneity of
variances were tested before eachANOVA. In all analyses, the
null hypothesis was rejected at 0.05 level.
Results
Transgene Expression Following AAV Vector Injection
Double immunofluorescence and laser confocal microsco-
py revealed that AAV9-vector injection induced overex-
pression of GFP or α-syn in dopaminergic neurons, but
not in microglia and astrocytes in rat SNpc. One week
after injection, we observed widespread labeling for GFP
or α-syn, which colocalized with the dopaminergic mark-
er TH showing efficient transduction of the nigral dopa-
minergic neurons. In keeping with our previous findings
[38], we did not find any significant colocalization be-
tween α-syn or GFP and the microglial population marker
Iba-1 or the astrocyte marker GFAP. In addition, TH-
negative (i.e., nondopaminergic) neurons were also la-
beled (Figs. 1 and 3a, h).
Fig. 1 Double
immunofluorescence for the
dopaminergic marker TH (a, d, g,
j), or the microglial marker Iba-1
(b, e, h, k), or the astrocytic
marker GFAP (c, f, i, l) (red) and
different transgenes (GFP: a–f; α-
syn-A53T: g–l) in the substantia
nigra region 1 week after the in-
jection of AAV9 expressing hu-
man GFP or human α-syn-A53T,
respectively (green). Laser confo-
cal microscopy shows
colocalization (yellow) of GFP or
α-syn-A53T with the dopaminer-
gic marker TH (a, d, g, j).
However, GFP or α-syn-A53T is
not expressed in microglia or as-
trocytes. Areas squared in (a)–(c)
and (g)–(i) are magnified in (d)–
(f) and (j)–(l), respectively. Scale
bars = 75 μm (a–c, g–i), 25 μm
(d), and 7.5 μm (e–f, j–l).
Abbreviations: AAV9 = adeno-
associated viral vectors serotype
9; α-syn A53T = A53T mutated
alpha-synuclein; GFAP = glial fi-
brillary acidic protein; GFP =
green fluorescent protein; Iba-1 =
ionized calcium-binding adapter
molecule 1; TH = tyrosine
hydroxylase
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Four weeks after injection, a clear loss of TH-positive cells
was observed in the SNpc of the lesioned groups. Despite the
intense microglial reaction observed in the ipsilateral ventral
mesencephalon (see below), labeling for α-syn was located in
neurons (Fig. 2a–f). However, some microglial phagocytic
cells showed engulfed α-syn (Fig. 2g–k). The pattern of
SNpc labeling and colocalization with dopaminergic neurons
and glial cells was similar forWTα-syn andA53Tmutatedα-
syn. Furthermore, intense labeling for phosphorylated α-syn
was observed in the surviving dopaminergic neurons in the
lesioned groups (Fig. 3b–g, i–l). Interestingly, the rate of phos-
phorylated α-syn/TH was not decreased in rats treated with
AT1 blockers in comparison with untreated rats, which sug-
gests that a decrease in α-syn phosphorylation is not a major
mechanism responsible for the neuroprotective effects of
candesartan and telmisartan described below (Fig. 3b, c).
Loss of Dopaminergic Neurons After Overexpression
of WT or Mutated A53T Alpha-Synuclein: Effect of AT1
Receptor Blockers
Consistent with that observed in previous studies with similar
animal models [13, 14], no appreciable loss of dopaminergic
neurons was observed (Fig. 4a) 1 week after injection. No
significant changes were observed in striatal TH-ir, suggesting
no significant loss of striatal dopaminergic terminals (Fig. 5a).
Four weeks after injection, a total number of 10,725 ± 621
(mean ± SEM) TH-positive neurons were counted in the ipsilat-
eral SNpc of saline-injected rats, which was not significantly
different from that observed in AAV9-α-syn-Ф-injected animals
(10,107 ± 503 neurons). Injection ofAAV9-WTα-syn induced a
loss of TH-ir neurons of about 57% (i.e., 4641 ± 329) (Fig. 4b,
d–f). The loss of neurons in the SNpc (not just TH
Fig. 2 Double and triple
immunofluorescence for (red) the
dopaminergic marker TH (a, d),
or the astrocytic marker GFAP (c,
f), or the microglial marker Iba-1
(b, e, g–k), or the nuclear marker
Hoechst 33342 (i–k; blue), and
different transgenes (green; α-
syn-WT: a–f; α-syn-A53T: g–k)
in the substantia nigra region
4 weeks after the injection of
AAV9 expressing human WT α-
syn (a–f) or human α-syn-A53T
(g–k), respectively. Laser confo-
cal microscopy shows
colocalization (yellow) of α-syn
with the dopaminergic marker TH
(a, d). However, α-syn is not
expressed in microglia or astro-
cytes. Areas squared in (a)–(c) are
magnified in (d)–(f). An intense
microglial activation is observed
in (b) and (e). A microglial cell
engulfing α-syn-A53T from a
degenerating neuron (arrow) is
shown in (g)–(k). Scale bars =
75 μm (a–c), 7.5 μm (d), 5 μm
(e–f), and 10 μm (g–k).
Abbreviations: α-syn A53T =
A53T mutated alpha-synuclein;
α-syn WT = wild-type alpha-sy-
nuclein; GFAP = glial fibrillary
acidic protein; Iba-1 = ionized
calcium-binding adapter mole-
cule 1; TH = tyrosine hydroxylase
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downregulation) was confirmed by counting neurons in Nissl-
stained sections. We observed 12,915 ± 312 Nissl-stained neu-
rons in controls and 11,397 ± 605 neurons in animals injected
with empty vectors. However, 5019 ± 340 Nissl-stained
neurons were counted in the AAV9-WT α-syn-injected group.
Similarly, injection of AAV9-A53T α-syn induced a marked
loss of Nissl-stained neurons (6409 ± 342) in comparison with
control rats or rats injected with AAV9 empty vectors (Fig.
Fig. 3 Expression of α-syn (a, h) and phosphorylated α-syn (b–g, i–l)
1 week (a, h) and 4 weeks (b–g, i–l) after injection of AAV9 vectors. The
rate of expression of α-syn in dopaminergic neurons (TH-ir) of rats
injected with AAV9-α-syn WT or AAV9-α-syn A53T is shown in (a).
The rate of expression of phosphorylated α-syn in dopaminergic neurons
(TH-ir) of rats injected with AAV9-α-syn WTor AAV9-α-syn A53T and
treated or not treated with candesartan or telmisartan is shown in (b) and
(c). The colocalization (yellow) of phosphorylated α-syn (red) and dopa-
minergic neurons (green) in the different experimental groups is illustrat-
ed in (d)–(g) and magnified in (j)–(l). The expression of α-syn 1 week
after injection (h) and phosphorylated α-syn in the nigral region (i.e.,
dopaminergic and nondopaminergic cells) 1 and 4 weeks after injection
(i) was confirmed by Western blot. Data are means ± SEM. *p < 0.05
relative to the group injected with saline; #p < 0.05 relative to the
AAV9-Ф-injected group. One-way ANOVA followed by Holm–Sidak
post hoc test. Scale bars = 250 μm (d–g) and 25 μm (j–l).
Abbreviations: α-syn A53T = A53T mutated alpha-synuclein; α-syn
WT = wild-type alpha-synuclein; ANOVA = analysis of variance;
CAND = candesartan; SEM = standard error of the mean; TELM =
telmisartan; Ф = empty-null
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4c). In addition, a loss of dopaminergic striatal terminals was
confirmed by optical density of striatal TH-ir both in rats
injected with AAV9-WT α-syn and rats injected with
AAV9-A53T α-syn, which showed a significant decrease in
striatal TH-ir relative to control rats or rats injected with
AAV9 empty vectors (Fig. 5b–f).
Rats injected with AAV9-WT α-syn and treated with the
AT1 receptor antagonist candesartan showed a significant loss
of dopaminergic neurons (6484 ± 460; about 40% decrease in
comparison with controls) and striatal dopaminergic termi-
nals; however, the neuron loss and striatal loss of dopaminer-
gic terminals were significantly less than those observed in
rats not treated with candesartan. A similar neuroprotective
effect was observed in AAV9-WT α-syn rats treated with
telmisartan (6484 ± 460 neurons; about 40% decrease in the
number of nigral neurons and the corresponding striatal dopa-
minergic terminals relative untreated controls). Similar neuro-
protective effects were observed in rats injected with AAV9-
A53Tα-syn and treated with candesartan or telmisartan (Figs.
4b, c, g–i and 5b, c, g–i). We also counted Nissl-stained neu-
rons to confirm the neuroprotective effects of candesartan,
showing a number of neurons (7066 ± 475 neurons in the
group injected with AAV9-WT α-syn; 8583 ± 518 in the
group injected with AAV9-A53T α-syn), which was signifi-
cantly higher than in lesioned and untreated rats (5019 ± 340
in the group injected with AAV9-WT α-syn; 6409 ± 342 in
the group injected with AAV9-A53T α-syn). Nissl-stained
neuron counts also confirmed the neuroprotective effects of
telmisartan, showing a number of neurons (8432 ± 494 neu-
rons in the group injected with AAV9-WT α-syn; 8523 ± 530
Fig. 4 Dopaminergic (TH-ir) neurons in the substantia nigra compacta
(SNc) of the noninjected side (contralateral, control) and 1 week (a) or
4 weeks (b–i) after injection of saline, or empty AAV9 vectors (AAV9-
Ф), or AAV9 expressing human WT α-syn, or AAV9 expressing human
A53Tmutatedα-syn in rats not treated or treated with the AT1 antagonist
candesartan (CAND) or telmisartan (TELM). Representative photomicro-
graphs of the substantia nigra compacta of different groups of rats are
shown in (d)–(i). The estimated total number of dopaminergic (TH-ir)
neurons in the substantia nigra compacta of the different experimental
groups is shown in (a)–(c). Data are means ± SEM. *p < 0.05 relative to
the noninjected side (contralateral, control), #p < 0.05 relative to the group
treated with saline, &p < 0.05 relative to the AAV9-Ф-injected group, $p
< 0.05 relative to the group injectedwith AAV9 expressing humanWTα-
syn (b) or expressing human A53Tmutatedα-syn (c). One-way ANOVA
and Holm–Sidak post hoc test. Scale bar = 200 μm. Abbreviations:
ANOVA = analysis of variance; SEM = standard error of the mean; Ф
= empty-null
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in the group injected with AAV9-A53T α-syn), which was
significantly higher than in lesioned and untreated rats (see
above). No significant differences were found between rats
injected with AAV9-WT α-syn and treated with candesartan
and rats injected with AAV9-WT α-syn and treated with
telmisartan.
HPLC Analysis and Motor Behavior
Four weeks after injection, consistent with the loss of do-
paminergic neurons in the SNpc and the loss of striatal
terminals, HPLC analysis revealed a marked decrease in
the levels of dopamine and metabolites (DOPAC and
HVA) in rats injected with AAV9-WT α-syn (Fig. 6a–d)
and rats injected with AAV9-A53T α-syn (Fig. 6e–h) in
comparison with controls. In addition, we observed an in-
crease in the DOPAC/DA ratio that suggested an increase
in DA turnover. Interestingly, the levels of dopamine and
metabolites significantly increased in lesioned rats treated
with candesartan or telmisartan (Fig. 6).
In the cylinder test, rotarod test, and open field locomo-
tor activity, rats injected with AAV9-WT α-syn (Fig. 7a–c)
and rats injected with AAV9-A53T α-syn (Fig. 7d–f)
showed a significant decrease in spontaneous use of the
impaired forepaw (Fig. 7a, d), rotarod performance (Fig.
7b, e), and locomotor activity (Fig. 7c, f), which were sig-
nificantly improved in lesioned rats treated with
candesartan or telmisartan.
Fig. 5 Optical densitometry of TH-ir striatal dopaminergic terminals of
the noninjected side (contralateral, control) and 1 week (a) or 4 weeks (b–
i) after injection of saline, or empty AAV9 vectors (AAV9-Ф), or AAV9
expressing humanWTα-syn, or AAV9 expressing humanA53Tmutated
α-syn in rats not treated or treated with the AT1 antagonists candesartan
(CAND) or telmisartan (TELM). Representative photomicrographs of the
striatal TH immunoreactivity of different groups of rats are shown in (d)–
(i). The optical densitometry of striatal TH-ir of the different experimental
groups is shown in (a)–(c). Data are means ± SEM. *p < 0.05 relative to
the noninjected side (contralateral, control), #p < 0.05 relative to the group
treated with saline, &p < 0.05 relative to the AAV9-Ф-injected group, $p
< 0.05 relative to the group injectedwith AAV9 expressing humanWTα-
syn (b) or expressing human A53Tmutatedα-syn (c). One-way ANOVA
and Holm–Sidak post hoc test. Scale bar = 500 μm. Abbreviations:
ANOVA = analysis of variance; SEM = standard error of the mean; Ф
= empty-null
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Microglial Response After Overexpression of WT
or Mutated A53T Αlpha-Synuclein: Effect of AT1
Receptor Blockers
One week after injection of AAV9-WT α-syn or AAV9-A53T
α-syn, the loss of dopaminergic neurons was not significant.
However, an increase in density of Iba-1-ir cells was observed
in the nigral region (Fig. 1h, k). Clear phagocytic phenotypes
were uncommon, particularly phagocytic microglia engulfing
neurons or syn-positive material. Four weeks after injection of
AAV9-WT α-syn or AAV9-A53T α-syn, the loss of dopami-
nergic neurons was accompanied by a marked increase in
microglial response as observed with Iba-1 labeling and con-
focal microscopy (Fig. 2b, e). Phagocytic microglial
Fig. 6 HPLC analysis of the
striatal levels of DA (a, e),
DOPAC (b, f), and HVA (c, g)
4 weeks after injection of AAV9
vectors in control groups and
groups injected with AAV9-α-
syn WT (a–d) or AAV9-α-syn
A53T (e–h). The striatal turnover
of DA calculated by the DOPAC/
DA ratio is also shown (d, h).
Measurements show significant
reductions in DA and metabolites
in lesioned rats relative to controls
(saline and empty vectors), which
were significantly improved by
treatment with candesartan or
telmisartan. Data are means ±
SEM. *p < 0.05 relative to the
saline-injected group; #p < 0.05
relative to the AAV9-Ф-injected
group; &p < 0.05 relative to the
group injected with AAV9 ex-
pressing human WT α-syn (a, b)
or expressing human A53T mu-
tated α-syn (e–h). One-way
ANOVA followed by Holm–
Sidak post hoc test.
Abbreviations: α-syn A53T =
A53T mutated alpha-synuclein;
α-syn WT = wild-type alpha-sy-
nuclein; ANOVA = analysis of
variance; CAND = candesartan;
DA = dopamine; DOPAC = 3,4-
dihydroxyphenylacetic acid;
HVA = homovanilic acid; SEM =
standard error of themean; TELM
= telmisartan; Ф = empty-null
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phenotypes were abundant and frequently showed engulfed
syn-positive material (Fig. 2g–k). The high number of mor-
phological phenotypes of classically activated microglia was
confirmed with immunohistochemistry for OX6 (MHC class
II). Rats injected with AAV9-WT α-syn or AAV9-A53T α-
syn showed significantly higher number of OX6-ir cells than
controls or rats injected with empty vectors. However, the
effects of α-syn on the microglial response were significantly
lower in rats treated with the AT1 blockers candesartan or
telmisartan (Figs. 8, 9, and 10).
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After observing the inhibitory effects of AT1 blockers on
dopaminergic cell death and microglial response induced by α-
syn overexpression, we investigated the effects of neuronal α-
syn overexpression on the RAS pro-oxidative pro-inflammatory
axis (Ang II/AT1/NADPH oxidase). Rats that overexpressed α-
syn showed an increase in the expression of AT1 receptors and
NADPH activity in the nigral region in comparison with control
rats injected with empty-null vectors, and this increase was
inhibited in rats treated with candesartan or telmisartan (Fig. 9a,
b, d). Consistent with the abovementioned observations, rats
injected with AAV9-α-syn showed a significant increase in the
expression of the marker of phagocytic activity CD68 (Fig. 9c)
andM1microglial phenotype makers (iNOS and TNF-α, IL-1β,
and IL-6) (Fig. 10a–e) and a significant decrease in the expres-
sion of the M2 microglial phenotype marker ARG-1 (Fig. 10f).
These changes in microglial phenotype markers were inhibited
by simultaneous treatment with the AT1 blockers candesartan or
telmisartan (Fig. 10a–f).
Fig. 8 OX6 immunoreactive microglial cells in the substantia nigra
compacta 4 weeks after injection of saline, or empty AAV9 vectors
(AAV9-Ф), or AAV9 expressing human WT α-syn, or AAV9
expressing human A53T mutated α-syn in rats not treated or treated with
the AT1 antagonist candesartan (CAND) or telmisartan (TELM).
Representative photomicrographs of the substantia nigra compacta of
different groups of rats are shown in (c)–(i). The estimated number of
OX6-ir cells in the substantia nigra of the different experimental groups is
shown in (a) and (b). The microglial cells are shown as% of that observed
in controls (i.e., saline-injected rats), and data are means ± SEM. *p < 0.05
relative to the group treated with saline, #p < 0.05 relative to the AAV9-Ф-
injected group, &p < 0.05 relative to the group injected with AAV9 ex-
pressing humanWTα-syn (a) or expressing human A53Tmutated α-syn
(b). One-way ANOVA and Holm–Sidak post hoc test. Scale bar =
100 μm. Abbreviations: ANOVA = analysis of variance; SEM = standard
error of the mean; Ф = empty-null
Fig. 7 Behavioral analysis of rats in different experimental groups
4 weeks after injection of AAV9 vectors. Motor performance was
analyzed using the cylinder test (a, d), the rotarod test (b, e), and the
open field test for locomotor activity (c, f). Measurements show
significant reductions in motor performance in lesioned rats relative to
controls (saline and empty vectors), which were significantly improved
by treatment with candesartan or telmisartan. Data are means ± SEM. *p
< 0.05 relative to saline-injected group; #p < 0.05 relative to the AAV9-Ф-
injected group; &p < 0.05 relative to the group injected with AAV9 ex-
pressing human WT α-syn (a–c) or expressing human A53T mutated α-
syn (d–f). One-way ANOVA followed by Holm–Sidak post hoc test.
Abbreviations: α-syn A53T = A53T mutated alpha-synuclein; α-syn
WT = wild-type alpha-synuclein; ANOVA = analysis of variance;
CAND = candesartan; SEM = standard error of the mean; TELM =
telmisartan; Ф = empty-null
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Discussion
In the present study, we observed that the AAV9-synapsin-α-
syn vector led to overexpression of α-syn in dopaminergic
neurons of the SNpc, which induced a marked dopaminergic
neuron loss together with a concomitant microglial
neuroinflammatory response. A similar level of dopaminergic
cell death was observed 4 to 5 weeks after the vector injection
in other recent models using efficient AAV vector constructs
[13, 14]. A 10% additional increase in cell death was observed
over the following 4 weeks in some studies [13]. However,
early time points (i.e., 1 and 4 weeks after injection) are more
adequate to study the direct α-syn effects on the microglial
response than more chronic or advanced stages. We injected
rats with AAV9 expressing WT or A53T mutated α-syn and
both led to marked neuron death and microglial activation. In
preliminary pilot experiments and consistent with previous
studies [39], we observed more toxic effects with the A53T
mutated α-syn constructs compared with WT α-syn. As a con-
sequence, a lower vector dose was used for A53T mutated α-
syn to get results more similar to that observed withWT α-syn.
Neuroinflammation is a major factor for progression of dopa-
minergic degeneration, and it has been suggested that the
microglial neuroinflammatory response may be a major mecha-
nism of α-syn toxicity [2, 6]. Consistent with this, an intense
neuroinflammatory response has been observed in the present
and previous studies using AAV viral vectors to induce α-syn
overexpression [15, 16]. On this basis, the present study has been
focused on the α-syn-mediated microglial response and, partic-
ularly, its possible modulation by AT1 receptor antagonists.
Several in vitro studies have observed that extracellular α-
syn can inducemicroglial activation and cause neuron damage
[4, 40, 41]. Interestingly, we observed a significant microglial
response 1 week after AAV vector injection (i.e., before the
observation of a significant neuron death), which suggests that
intraneuronal α-syn accumulation may trigger the microglial
Fig. 9 Effect of empty AAV9 vectors (AAV9-Ф) or AAV9 expressing
human α-syn on the expression of AT1 receptor mRNA, NADPH activ-
ity, and markers of phagocytic activity (CD68) in rats not treated or
treated with the AT1 antagonist candesartan (CAND) or telmisartan
(TELM). AAV9 expressing human WT α-syn induced a significant in-
crease in the expression of AT1 receptor mRNA (a), NADPH activity (b,
d), and CD68 (c). A significant increase in NADPH activity induced by
AAV9 expressing human A53T α-syn is shown in (d). These changes
were inhibited by simultaneous treatment with the AT1 blockers
candesartan or telmisartan (a–d). In (a) and (c), the results were normal-
ized to the values of the control group. For RT-PCR, the comparative
cycle threshold values method (2−ΔΔCt) was used. Gene expression was
measured relative to that of the housekeeping transcripts (β-actin).
NADPH oxidase activity was expressed as relative light units (RLU)/
min/mg protein). Data are means ± SEM. *p < 0.05 relative to the
AAV9-Ф-injected group; #p < 0.05 relative to the group injected with
AAV9 expressing human α-syn. One-way ANOVA followed by Holm–
Sidak post hoc test. Abbreviations: α-syn A53T = A53T mutated alpha-
synuclein;α-synWT =wild-type alpha-synuclein; ANOVA = analysis of
variance; AT1 = angiotensin type 1 receptor; CAND= candesartan; CD68
= cluster of differentiation 68; SEM = standard error of the mean; TELM
= telmisartan; Ф = empty-null
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response before neuron death. It is likely that signals derived
from neurons altered byα-syn accumulation orα-syn released
by neurons independently of cell death [42] initiate the
microglial response. At later stages, a direct effect of the
extracellular synuclein released from degenerated neurons
can further activate microglia. In addition, microglia-
mediated neuroinflammation and α-syn–induced neuronal
damage may stimulate each other in a positive feedback self-
Fig. 10 Effect of empty AAV9 vectors (AAV9-Ф) or AAV9 expressing
humanα-syn on the expression of markers of the microglial phenotype in
rats not treated or treated with the AT1 antagonist candesartan (CAND) or
telmisartan (TELM). AAV9 expressing human WT α-syn induced a sig-
nificant increase in the expression of markers of the M1 cytotoxic phe-
notype (IL-1β, IL-6, iNOS, and TNF-α; a–d). The marked increase in
TNF-α expression induced by AAV9 expressing human A53T α-syn is
shown in (e). However, a decrease in the expression of the M2 repair/
regenerative phenotype marker ARG-1 was observed (f). These changes
were inhibited by simultaneous treatment with the AT1 blockers
candesartan or telmisartan (a–f). The results were normalized to the
values of the control group. For RT-PCR, the comparative cycle threshold
values method (2−ΔΔCt) was used. Gene expression was measured
relative to that of the housekeeping transcripts (β-actin). The levels of
TNF-α were quantified with rat specific enzyme-linked immunosorbent
assay (ELISA) kits in picograms per milliliter protein and expressed as
percentages of the content in the control group samples. Data are means ±
SEM. *p < 0.05 relative to the AAV9-Ф-injected group; #p < 0.05 relative
to the group injected with AAV9 expressing human α-syn. One-way
ANOVA followed by Holm–Sidak post hoc test. Abbreviations: α-syn
A53T = A53T mutated alpha-synuclein; α-syn WT, wild-type alpha-sy-
nuclein; ANOVA = analysis of variance; ARG-1 = arginase-1; CAND =
candesartan; IL-1β = interleukin-1β; IL-6 = interleukin 6; iNOS = induc-
ible nitric oxide synthase; TELM = telmisartan; TNF-α = tumor necrosis
factor alpha; SEM = standard error of the mean; Ф = empty-null
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perpetuating progression of neurodegeneration. The mecha-
nisms underlying microglial activation have not yet been to-
tally clarified. However, activation of the microglial response
by lesioned neurons has been shown in numerous studies [43,
44]. Furthermore, several in vitro studies have observed that
α-syn may activate Toll-like receptors of microglial cells and
stimulate different microglial activation pathways, including
the NF-κB and mitogen-activated protein kinase pathways
(for review, see Zhang et al. [6]). It was also shown that α-
syn induces microglial migration [45]. Interestingly, it has
been observed that microglial NADPH oxidase (PHOX) is
activated by the α-syn [38, 39]. Activation of NADPH oxi-
dase induces superoxide release and plays a pivotal role in
microglial polarization to a pro-inflammatory phenotype,
which can be inhibited by NADPH oxidase depletion or inhi-
bition [46, 47]. The observation of NADPH activation by α-
syn is of particular interest for the present study, because it is
well known that the pro-inflammatory axis of the RAS (Ang
II/AT1) is a major activator of the NADPH oxidase complex
in different cell types, and particularly in inflammatory cells
such as microglial cells [18, 48]. Pro-inflammatory signals
increase microglial AT1 receptor expression and activity
[49], and Toll-like receptors, which are known to mediate
classical microglial activation, may interact with AT1 recep-
tors [50, 51]. Furthermore, we have recently shown an impor-
tant interaction between RAS, NADPH oxidase, and Rho-
kinase (ROCK) in microglia [18, 52, 53]. It is known that
RhoA/ROCK is an important regulator of the actin cytoskel-
eton, which is particularly important for migration of inflam-
matory cells, including microglia [54], into inflamed areas and
for several changes involved in phagocytosis [55]. However,
the relationship between α-syn and microglial phagocytosis
has been controversial, and both positive and negative effects
have been observed in vitro [56, 57], which may be a conse-
quence of different forms of α-syn and experimental condi-
tions used [58]. In the present study, we observed evident
phagocytosis of α-syn by microglial cells 4 weeks after
AAV9-α-syn injections.
In the present in vivo model of overexpression α-syn,
using an effective AAV9-α-syn vector that restricts trans-
gene expression exclusively to neurons, we have shown
that both neuronal WT and A53T mutated α-syn lead to
dopaminergic neuron death and intense microglial pro-
inflammatory response. We observed a marked increase
in the number of OX6-positive microglial cells together
with an increase in the expression of the marker of
phagocytic activity CD68 and classical pro-inflammato-
ry/M1 microglial phenotype markers such as iNOS,
TNF-α, IL-1β, and IL-6 [59], and a significant decrease
in the expression of markers of immunoregulatory/M2
microglial phenotype such as the enzyme ARG-1 [59,
60]. Interestingly, an inhibition of the microglial re-
sponse led to a significant decrease in dopaminergic
neuron death, which confirms in the present in vivo mod-
el a significant role of the microglial response in α-syn-
induced dopaminergic neuron death and that modulation
of the microglial response may be a useful therapeutical
strategy. In the present study, we also showed that the
brain RAS plays a major role in the α-syn-induced
microglial response and α-syn-induced dopaminergic
neuron death.
In several previous studies, we have shown the pres-
ence of a local paracrine RAS in neurons and glial cells
in the substantia nigra and striatum of rodents and pri-
mates, including humans [61, 62]. This local RAS appears
normally involved in the regulation of dopamine levels
[63–65], modulation of intraneuronal levels of oxidative
stress [66–68], and modulation of the neuroinflammatory
response [18, 69]. In microglial cells, Ang II, via AT1
receptors, is a major activator of the microglial NADPH
oxidase complex and microglial polarization toward the
M1 pro-oxidative pro-inflammatory phenotype [17, 18]
and modulates levels of microglial pro-inflammatory cyto-
kines (such as TNF-α) and ROCK activity [52, 53, 70].
In the present in vivo study, we observed that overexpres-
sion of neuronal α-syn leads to increased expression of
AT1 and NADPH oxidase activity together with an in-
crease in microglial activation toward the M1 pro-
inflammatory phenotype. Consistent with this, administra-
tion of AT1 blockers such as candesartan and telmisartan
led to a significant decrease in the number of OX6-ir
microglial cells, expression of CD68 mRNA, NADPH ac-
tivity, expression of M1 phenotype markers, and α-syn-
induced dopaminergic neuron death. Candesartan and
telmisartan are the most effective AT1 blockers at crossing
the blood–brain barrier, and low doses not affecting blood
pressure are able to induce effects on brain RAS in vivo
[71, 72] and in vitro [52, 73]. In addition to the inhibition
of the Ang II/AT1/NADPH oxidase axis, candesartan and
telmisartan may protect against dopaminergic neuron death
by additional mechanisms. AT1 antagonists, particularly
telmisartan, may lead to activation of the anti-
inflammatory PPAR-γ receptors by a double mechanism
that involves a pharmacological AT1-independent
PPAR-γ agonistic effect and a direct effect of the block-
age of the AT1 itself, which also induces PPAR-γ activa-
tion [24, 74]. Regulation of α-syn levels and neurotrophic
factors (BDNF and GDNF) have also been suggested as
additional mechanisms involved in telmisartan-mediated
neuroprotection [75, 76]. The present results reveal that
inhibition of the microglial activation is a major mecha-
nism involved in the neuroprotective effect of candesartan
and telmisartan on the dopaminergic cell death induced by
α-syn overexpression. Our results suggest the repurposing
of candesartan and telmisartan as neuroprotective strategy
for PD.
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